First, we examined the RAB21 levels in serum EVs by western blot analysis using CD9 as an EV marker and confirmed that RAB21 was more abundant in the serum EVs of FTC patients than in those of FTA patients (Figs. 3 and S1B). This evidence concerns the gene CD9 and thyroid cancer, nonmedullary, 2.